Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma

被引:132
作者
Bardet, Stephane [1 ,2 ]
Malville, Elodie [3 ]
Rame, Jean-Pierre [4 ]
Babin, Emmanuel [5 ]
Samama, Guy [6 ]
De Raucourt, Dominique [4 ]
Michels, Jean-Jacques [7 ]
Reznik, Yves [3 ]
Hecnry-Amar, Michel [8 ]
机构
[1] Ctr Francois Baclesse, Dept Nucl Med, F-14076 Caen 05, France
[2] Ctr Francois Baclesse, Thyroid Unit, F-14076 Caen, France
[3] Univ Hosp, Dept Endocrinol, Caen, France
[4] Ctr Francois Baclesse, Dept Head & Neck Surg, F-14076 Caen 05, France
[5] Univ Hosp, Dept Head & Neck Surg, Caen, France
[6] Univ Hosp, Dept Gen Surg, Caen, France
[7] Ctr Francois Baclesse, Dept Pathol, F-14076 Caen 05, France
[8] Ctr Francois Baclesse, Clin Res Unit, F-14076 Caen 05, France
关键词
D O I
10.1530/EJE-07-0603
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Whether lymph-node dissection (LND) influences the lymph-node recurrence (LNR) risk in patients with papillary thyroid cancer remains controversial. The prognostic impact of macroscopic and microscopic lymph-node involvement at diagnosis is also an unresolved issue. A retrospective study was conducted to assess the influence of various LND procedures and to search for LNR risk factors. Methods: Overall 545 patients without distant metastases prior to surgery and main tumour >= 10 min were included. A total thyroidectomy was performed in all patients with either no LND (Group 1, n= 161), bilateral LND of the central and lateral compartments (Group 2, n = 181) or all other dissection modalities (Group 3, n = 2 03). Post-operative radioiodine was given to 496 (91%) patients. The 10-year cumulative probability of LNR was assessed and a prognostic study using multivariate analysis was performed. Results: Macroscopic lymph-node metastases were present in 118 patients, 57 diagnosed before surgery and 61 only at surgery (including 81% in the central compartment). Overall, the 10-year cumulative probability of LNR was 7%. Macroscopic lymph-node metastases (P=0.001), extra-thyroidal invasion (P=0.017) and male gender (P=0.05) were independent risk factors, while bilateral LND of the central and lateral compartments was protective (P=0.028). In patients with macroscopic lymph-node metastases, the 10-year probability was lower in Group 2 than in Group 3 (10%, vs 30%, P < 0.01). In patients without macroscopic lymph-node metastases (n = 427), no significant differences were observed between the three LND groups. Conclusions: Patients with macroscopic, but not microscopic, lymph-node involvement have a major LNR risk and need an optimal LND at primary surgery.
引用
收藏
页码:551 / 560
页数:10
相关论文
共 27 条
[1]  
Cady B, 1998, Surg Oncol Clin N Am, V7, P633
[2]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424
[3]   PAPILLARY THYROID-CARCINOMA [J].
HAY, ID .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1990, 19 (03) :545-576
[4]   Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients [J].
Hay, ID ;
Thompson, GB ;
Grant, CS ;
Bergstralh, EJ ;
Dvorak, CE ;
Gorman, CA ;
Maurer, MS ;
McIver, B ;
Mullan, BP ;
Oberg, AL ;
Powell, CC ;
van Heerden, JA ;
Goellner, JR .
WORLD JOURNAL OF SURGERY, 2002, 26 (08) :879-885
[5]  
HAY ID, 1989, SURGERY, V114, P1050
[6]   Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: Massive but not minimal extension affects the relapse-free survival [J].
Ito, Y ;
Tomoda, C ;
Uruno, T ;
Takamura, Y ;
Miya, A ;
Kobayashi, K ;
Matsuzuka, F ;
Kuma, K ;
Miyauchi, A .
WORLD JOURNAL OF SURGERY, 2006, 30 (05) :780-786
[7]   Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis [J].
Leboulleux, S ;
Rubino, C ;
Baudin, E ;
Caillou, B ;
Hartl, DM ;
Bidart, JM ;
Travagli, JP ;
Schlumberger, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5723-5729
[8]  
LEBOULLEUX S, 2007, J CLIN ENDOCRINOLOGY, V594, P3590
[9]   Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients [J].
Loh, KC ;
Greenspan, FS ;
Gee, L ;
Miller, TR ;
Yeo, PPB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (11) :3553-3562
[10]   Current approaches to primary therapy for papillary and follicular thyroid cancer [J].
Mazzaferri, EL ;
Kloos, RT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) :1447-1463